维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

13篇 您的检索式：作者名="Scheuring U"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Therapy withimatinib mesylate (Glivec) preceding allogeneic stem celltransplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) 显示文摘	Wassmann B Pfeifer H Scheuring U	2002	Leukemia2002，16，12：	1
	2	显示文摘	Wassmann B Pfeifer H Scheuring U	2002	Leukemia2002，，16：	1
	3	Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib显示文摘	Wassmann B Pfeifer H Scheuring U J	2004	Blood2004，103，4：	1
	4	Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lympho- blastic leukemia ( Ph + ALL) 显示文摘	Wassmann B Scheuring U Pfeifer H	2003	Leukemia2003，17，10：	1
	5	Therapy with imatinib mesylate (Glivec)preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia( Ph + ALL) 显示文摘	Wassmann B Pfeifer H Scheuring U	2002	Leukemia2002，16，12：	1
	6	Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr/Abl positive acute lymphoblastic leukemia with the Abltyrosine kinase inhibitor imatinib (STI571)显示文摘	SCHEURING U J PFEIFER H WASSMANN B	2003	Blood2003，101，：	1
	7	Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) 显示文摘	WASSMANN B SCHEURING U PFEIFER H	2003	Leukemia2003，17，：	1
	8	Early prediction of response in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastie leukemia (Ph+ALL) treated with imatinib mesylate (Glivec) 显示文摘	Wassmann B Pfeifer H Scheuring U J	2004	Blood2004，103，4：	1
	9	A randomized multicenter open Label phase Ⅱ study to determine the safty and efficacy of induction th-Erapy with imatinib (Glivec,formerly sti571)jin comparison with standard Induction chemotherapy in ekderly (>55years)patients with Ph+/BCR-ABL+ALL (CSTI571ADE10)显示文摘	Wassmann B Gokbuget N Scheuring U J	2003	Ann Hemotol2003，82，11：	1
	10	Efficacy and safety of Imatinib mesylate(Glivec) in combination with interferon-a- lpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph^+ ALL)显示文摘	Wassmann B Scheuring U Pfeifer H	2003	Leukemia2003，17，10：	1
	11	Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantion (SCT)in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia(Ph+ALL) 显示文摘	Wassmann B Pfeifer H Scheuring U	2002	Leukemia2002，16，12：	1
	12	Efficacy and safety of imatinib mesylate ( Glivec^TM) in combination with interferon-α ( IFN- α)in Philadelphia chromosome-positive acute lymphoblastie leukemia(Ph +ALL) 显示文摘	Wassmann B Scheuring U Pfeifer H	2003	Leukemia2003，17，10：	1
	13	Efficacy and safety of imatinib mesylate (GliveeTM)in combination with interferon-a (IFN-a) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) 显示文摘	WASSMANN B SCHEURING U PFEIFER H	2003	Leukemia2003，17，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费